{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:01:44Z","timestamp":1790341304808,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Sleep"],"abstract":"<jats:p>Chronic pain prevalence is increased in the sleep disorder narcolepsy, but the underlying reason for this remains debated. This mini review summarizes and discusses current evidence on links between narcolepsy type 1 (NT1) and type 2 (NT2) and chronic pain, exploring whether pain is best understood as a consequence of the pathophysiology or secondary to its manifestations and comorbidities. Registry-based and self-reported data indicate a high prevalence of chronic pain in NT1, while objective pain tests show inconsistent differences between NT1 and healthy individuals. This discrepancy suggests involvement of secondary mechanisms not readily captured by experimental pain testing. Comparable pain prevalence in NT1 and NT2 also speaks against orexin deficiency as a sole driver of chronic pain in NT1. Alternatively, altered dopaminergic signaling downstream of orexin could be a shared contributor to pain in NT1 and other fatigue-related conditions. Finally, the presence of activating autoantibodies in NT1 suggests a possible immune-mediated component for some patients. Overall, chronic pain is highly prevalent in both NT1 and NT2. It likely arises from a combination of neurobiological and psychological factors, with immune mechanisms as a possible additional contributor, rather than, in NT1, orexin dysfunction alone. This perspective highlights the clinical need for more holistic treatment approaches and for future studies with improved case-control matching, larger NT1 samples, especially among patients with chronic pain, and more detailed comparisons with NT2.<\/jats:p>","DOI":"10.3389\/frsle.2026.1930803","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:38:20Z","timestamp":1790339900000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic pain in narcolepsy reflects interacting neurobiological and psychological mechanisms: a mini-review"],"prefix":"10.3389","volume":"5","author":[{"given":"Maria","family":"Munch-Menzer","sequence":"first","affiliation":[{"name":"Department of Neuroscience, University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte Rahbek","family":"Kornum","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.5664\/jcsm.10906","article-title":"Headache improves with armodafinil","volume":"20","author":"Barone","year":"2024","journal-title":"J. Clin. Sleep Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6917","DOI":"10.3390\/app13126917","article-title":"Muscle pain sensitivity and prevalence of temporomandibular disorders in patients with narcolepsy with cataplexy: a controlled cohort study","volume":"13","author":"Bartolucci","year":"2023","journal-title":"Appl. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.pain.2004.02.005","article-title":"Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area","volume":"109","author":"Bartsch","year":"2004","journal-title":"Pain"},{"key":"B4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment","volume":"15","author":"Bassetti","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"RC168","DOI":"10.1523\/JNEUROSCI.21-19-j0003.2001","article-title":"Orexin (Hypocretin) neurons contain dynorphin","volume":"21","author":"Chou","year":"2001","journal-title":"J. Neurosci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.sleep.2017.11.1125","article-title":"Comorbidities in a community sample of narcolepsy","volume":"43","author":"Cohen","year":"2018","journal-title":"Sleep Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e12715","DOI":"10.1111\/jsr.12715","article-title":"Chronic pain in narcolepsy type 1 and type 2 \u2013 an underestimated reality","volume":"28","author":"Cremaschi","year":"2018","journal-title":"J. Sleep Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.sleep.2011.01.010","article-title":"High pain frequency in narcolepsy with cataplexy","volume":"12","author":"Dauvilliers","year":"2011","journal-title":"Sleep Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jpain.2013.08.007","article-title":"The association of sleep and pain: an update and a path forward","volume":"14","author":"Finan","year":"2013","journal-title":"J. Pain."},{"key":"B10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.smrv.2012.03.003","article-title":"The comorbidity of insomnia, chronic pain, and depression: dopamine as a putative mechanism","volume":"17","author":"Finan","year":"2013","journal-title":"Sleep Med. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.5665\/sleep.2706","article-title":"Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study","volume":"36","author":"Jennum","year":"2013","journal-title":"Sleep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.2147\/JPR.S471401","article-title":"The combined effect between sleep disorders and depression symptoms on chronic low back pain: a cross-sectional study of NHANES","volume":"17","author":"Jiang","year":"2024","journal-title":"J. Pain Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"170928","DOI":"10.1016\/j.peptides.2022.170928","article-title":"The opposite roles of orexin neurons in pain and itch neural processing","volume":"160","author":"Kaneko","year":"2023","journal-title":"Peptides."},{"key":"B14","doi-asserted-by":"publisher","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"B15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12325-021-01992-4","article-title":"Current understanding of narcolepsy 1 and its comorbidities: what clinicians need to know","volume":"39","author":"Krahn","year":"2022","journal-title":"Adv. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1021\/jm030982t","article-title":"Structure-activity studies of orexin a and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands","volume":"47","author":"Lang","year":"2004","journal-title":"J. Med. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41577-023-00902-9","article-title":"The immunopathogenesis of narcolepsy type 1","volume":"24","author":"Liblau","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/sleepadvances\/zpae067","article-title":"Demographic characteristics and comorbidities of patients with narcolepsy: a propensity-matched cohort study","volume":"5","author":"Lipford","year":"2024","journal-title":"Sleep Adv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.sleep.2020.11.038","article-title":"Activating autoantibodies against G protein-coupled receptors in narcolepsy type 1","volume":"77","author":"Orjatsalo","year":"2021","journal-title":"Sleep Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/cne.10860","article-title":"Hypothalamic orexin (hypocretin) neurons express vesicular glutamate transporters VGLUT1 or VGLUT2","volume":"465","author":"Rosin","year":"2003","journal-title":"J. Compar. Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41598-018-36942-8","article-title":"HPLC. analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy","volume":"9","author":"Sakai","year":"2019","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"106014","DOI":"10.1016\/j.neubiorev.2025.106014","article-title":"Altered pain perception and nociceptive thresholds in major depression and anxiety disorders: a meta-analysis","volume":"169","author":"Scaini","year":"2025","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.sleep.2014.09.018","article-title":"Pain perception in narcolepsy with cataplexy patients","volume":"16","author":"Spielberger","year":"2015","journal-title":"Sleep Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/14737175.2024.2328728","article-title":"Orexins and primary headaches: an overview of the neurobiology and clinical impact","volume":"24","author":"Stanyer","year":"2024","journal-title":"Expert. Rev Neurother."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/isbn.978-3-318-06844-3","article-title":"The Orexin System","author":"Steiner","year":"2021","journal-title":"Basic Science and Role in Sleep Pathology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/npr2.12094","article-title":"OX(2) receptors mediate the inhibitory effects of orexin-A on potassium chloride-induced increases in intracellular calcium ion levels in neurons derived from rat dorsal root ganglion in a chronic pain model","volume":"40","author":"Yamaguchi","year":"2020","journal-title":"Neuropsychopharmacol. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"102458","DOI":"10.1016\/j.npep.2024.102458","article-title":"The protective effects of orexin B in neuropathic pain by suppressing inflammatory response","volume":"108","author":"Zhu","year":"2024","journal-title":"Neuropeptides."}],"container-title":["Frontiers in Sleep"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frsle.2026.1930803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:38:21Z","timestamp":1790339901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frsle.2026.1930803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":29,"alternative-id":["10.3389\/frsle.2026.1930803"],"URL":"https:\/\/doi.org\/10.3389\/frsle.2026.1930803","relation":{},"ISSN":["2813-2890"],"issn-type":[{"value":"2813-2890","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1930803"}}